A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada (NCT05424562)
Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax (LIVEN)
🩺 Plain-English Summary (8th-Grade Level)
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax works to treat AML in adult participants who are ineligible for intensive induction chemotherapy in Canada. Venetoclax is a drug approved to treat Acute Myeloid Leukemia (AML). All study participants will receive Venetoclax as prescribed by their study doctor in accordance with approved local label. Adult participants with a new diagnosis of AML who are ineligible for intensive induction chemotherapy will be enrolled. Around 200 participants will be enrolled in the study in approximately 15-20 sites in Canada. Participants will receive venetoclax tablets to be taken by mouth daily according to the approved local label. The duration of the study is approximately 36 months. There is expected to be no additional burden for participants in this trial. All study visits will occur during routine clinical practice and participants will be followed for 36 months.
Who can join: Review the eligibility criteria below.
Location: Tom Baker Cancer Centre /ID# 248113 — Calgary, Alberta
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Tom Baker Cancer Centre /ID# 248113 — Calgary, Alberta
- University of Alberta Hospital /ID# 251531 — Edmonton, Alberta
- BC Cancer - Surrey /ID# 257515 — Surrey, British Columbia
- Vancouver General Hospital /ID# 245438 — Vancouver, British Columbia
- BC Cancer - Victoria /ID# 257339 — Victoria, British Columbia
- CancerCare Manitoba /ID# 246414 — Winnipeg, Manitoba
- The Moncton Hospital /ID# 247277 — Moncton, New Brunswick
- Eastern Regional Health Authority /ID# 250241 — St. John's, Newfoundland and Labrador
- Queen Elizabeth II Health Sciences Centre - Victoria General /ID# 246514 — Halifax, Nova Scotia
- Juravinski Cancer Centre /ID# 247183 — Hamilton, Ontario
- Kingston Health Sciences Centre /ID# 253439 — Kingston, Ontario
- London Health Sciences Center- University Hospital /ID# 248027 — London, Ontario
- Lakeridge Health - Oshawa /ID# 246412 — Oshawa, Ontario
- Thunder Bay Regional Research Institute /ID# 249163 — Thunder Bay, Ontario
- Sunnybrook Health Sciences Centre /ID# 251966 — Toronto, Ontario
- University Health Network_Princess Margaret Cancer Centre /ID# 249607 — Toronto, Ontario
- Disc_Royal Victoria Hospital / McGill University Health Centre /ID# 249704 — Montreal, Quebec
- CIUSSS de l'Estrie - CHUS /ID# 248915 — Sherbrooke, Quebec
- Allan Blair Cancer Centre /ID# 247663 — Regina, Saskatchewan
- Saskatoon Cancer Centre /ID# 247181 — Saskatoon, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.